Show simple item record

FieldValueLanguage
dc.contributor.authorReyes, Saulen
dc.contributor.authorCunningham, Anthony Len
dc.contributor.authorKalincik, Tomasen
dc.contributor.authorHavrdova, Eva Kubalaen
dc.contributor.authorIsobe, Norikoen
dc.contributor.authorPakpoor, Juliaen
dc.contributor.authorAiras, Lauraen
dc.contributor.authorBunyan, Reem Fen
dc.contributor.authorvan der Walt, Annekeen
dc.contributor.authorOh, Jiwonen
dc.contributor.authorMathews, Joelaen
dc.contributor.authorMateen, Farrah Jen
dc.contributor.authorGiovannoni, Gavinen
dc.date.accessioned2021-07-22T22:39:00Z
dc.date.available2021-07-22T22:39:00Z
dc.date.issued2021
dc.identifier.urihttps://hdl.handle.net/2123/25755
dc.description.abstractIn this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.en
dc.language.isoenen
dc.rightsOther
dc.subjectCOVID-19en
dc.subjectCoronavirusen
dc.titleUpdate on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. [Review]en
dc.typeArticleen
dc.identifier.doi10.1016/j.jneuroim.2021.577627
usyd.facultySeS faculties schools::Faculty of Medicine and Healthen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.